Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Launched by NATIONAL UNIVERSITY OF MALAYSIA · Dec 15, 2022
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
This prospective, open-label, randomised controlled trial will be conducted in the Intensive Care Unit (ICU) of Universiti Kebangsaan Malaysia Medical Centre (UKMMC). This study protocol will therefore be submitted for the approval of both the Research Committee of Anaesthesiology \& Intensive Care Unit, UKKMC and the Research \& Ethics Committee of UKMMC prior to its commencement. Written and informed consent will be obtained from the next of kin prior to the commencement of study by the medical doctors in charge of admitting the patients to ICU. These healthcare professionals will be rece...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged \> 18 years old
- • Mechanically ventilated due to severe community or hospital acquired pneumonia
- Exclusion Criteria:
- • Patients aged \<18 years old
- • Pregnant and lactating patients
- • Patients with known allergies to ambroxol hydrochloride
- • Patients with aspartate aminotransferase (AST) \>5 times the upper limit of normal at the time of recruitment
- • Moribund patients who are expected to not survive within 24 hours of ICU admission
About National University Of Malaysia
The National University of Malaysia (Universiti Kebangsaan Malaysia, UKM) is a prestigious institution dedicated to advancing medical research and clinical trials that contribute significantly to the fields of healthcare and biomedical sciences. As a leading academic and research university, UKM is committed to fostering innovation and excellence in clinical research, promoting collaboration among multidisciplinary teams, and enhancing the quality of patient care. The university's robust infrastructure and experienced research faculty facilitate rigorous clinical trials aimed at addressing critical health challenges, thereby improving health outcomes both locally and globally. Through its dedication to ethical research practices and adherence to regulatory standards, UKM strives to enhance the understanding of diseases and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cheras, Kuala Lumpur, Malaysia
Patients applied
Trial Officials
Associate Professor Dr. Aliza Mohamad Yusof, MD (UKM)
Principal Investigator
Hospital Tuanku Muhriz UKM (HCTM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials